Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment
60
Participants
Timeline
Start Date
July 9, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Conditions
Pulmonary FibrosisCOVID-19 PneumoniaLong COVID
Interventions
DRUG
Sirolimus
Triangular-shaped tablet
Trial Locations (1)
60637
University of Chicago, Chicago
All Listed Sponsors
lead
University of Chicago
OTHER
NCT04948203 - Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | Biotech Hunter | Biotech Hunter